Role of positron emission tomography in the (re-)staging of oesophageal cancer

References

• Daly JM, Fry WA, Little AG, Winchester DP, McKee RF, Stewart AK, et al. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J Am Coll Surg 2000; 190: 562–72
   PubMed Web of Science ®Google Scholar
• Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77: 845–57
   PubMed Web of Science ®Google Scholar
• Ancona E, Ruol A, Santi S, Merigliano S, Sileni VC, Koussis H, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165–74
   PubMed Web of Science ®Google Scholar
• Law S, Fok M, Chow S, Chu KM, Wong J. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210–17
   PubMed Web of Science ®Google Scholar
• Wolfman NT, Scharling ES, Chen MY. Esophageal squamous carcinoma. Radiol Clin North Am 1994; 32: 1183–201
   PubMedGoogle Scholar
• Van Dam J. Endosonographic evaluation of the patient with esophageal cancer. Chest 1997; 112 Suppl 4: 184S–90S
   Google Scholar
• Fockens P, Manshanden CG, van Lanschot JJ, Obertop H, Tytgat GN. Prospective study on the value of endosonographic follow-up after surgery for esophageal carcinoma. Gastrointest Endosc 1997; 46: 487–91
   PubMedGoogle Scholar
• Earlam R, Cunha-Melo JR. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br J Surg 1980; 67: 457–61
   PubMedGoogle Scholar
• Bar-Shalom R, Valdivia AY, Blaufox MD. PET imaging in oncology. Semin Nucl Med 2000; 30: 150–85
   PubMed Web of Science ®Google Scholar
• Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000; 18: 3202–10
   PubMed Web of Science ®Google Scholar
• Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998; 39: 1002–7
   PubMed Web of Science ®Google Scholar
• Kneist W, Schreckenberger M, Bartenstein P, Grunwald F, Oberholzer K, Junginger T. Positron emission tomography for staging esophageal cancer: does it lead to a different therapeutic approach?. World J Surg 2003; 27: 1105–12
   PubMedGoogle Scholar
• van Westreenen HL, Westerterp M, Bossuyt PM, Pruim J, Sloof GW, van Lanschot JJ, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004; 22: 3805–12
   PubMed Web of Science ®Google Scholar
• Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997; 64: 770–6
   PubMed Web of Science ®Google Scholar
• Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000; 41: 808–15
   PubMed Web of Science ®Google Scholar
• Jager PL, Que TH, Vaalburg W, Pruim J, Elsinga P, Plukker JT. Carbon-11 choline or FDG-PET for staging of oesophageal cancer?. Eur J Nucl Med 2001; 28: 1845–9
   PubMedGoogle Scholar
• Junginger T, Kneist W, Schreckenberger M, Menzel C, Oberholzer K, Bartenstein P. Positronen-Emissions-Tomographie zum präoperativen Staging des Ösophaguskarzinoms. Dtsch Med Wochenschr 2003; 127: 1935–41
   Google Scholar
• Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Ojima H, et al. Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 2002; 94: 921–8
   PubMedGoogle Scholar
• Kobori O, Kirihara Y, Kosaka N, Hara T. Positron emission tomography of esophageal carcinoma using (11)C- choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86: 1638–48
   PubMedGoogle Scholar
• Kole AC, Plukker JT, Nieweg OE, Vaalburg W. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy. Br J Cancer 1998; 78: 521–7
   PubMedGoogle Scholar
• Meltzer CC, Luketich JD, Friedman D, Charron M, Strollo D, Meehan M, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography. Clin Nucl Med 2000; 25: 882–7
   PubMed Web of Science ®Google Scholar
• Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998; 53: 659–65
   PubMedGoogle Scholar
• Wren SM, Stijns P, Srinivas S. Positron emission tomography in the initial staging of esophageal cancer. Arch Surg 2002; 137: 1001–6
   PubMedGoogle Scholar
• Yoon YC, Lee KS, Shim YM, Kim BT, Kim K, Kim TS. Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection–prospective study. Radiology 2003; 227: 764–70
   PubMedGoogle Scholar
• Cochrane methods working group on systematic review of screening and diagnostic tests. Recommended methods. Cochrane; 6-6-1996.
   Google Scholar
• Kato H, Miyazaki T, Nakajima M, Takita J, Kimura H, Faried A, et al. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 2005; 103: 148–56
   PubMedGoogle Scholar
• Rasanen JV, Sihvo EI, Knuuti MJ, Minn HR, Luostarinen ME, Laippala P, et al. Prospective analysis of accuracy of positron emission tomography, computed tomography, and endoscopic ultrasonography in staging of adenocarcinoma of the esophagus and the esophagogastric junction. Ann Surg Oncol 2003; 10: 954–60
   PubMed Web of Science ®Google Scholar
• Sihvo EI, Rasanen JV, Knuuti MJ, Minn HR, Luostarinen ME, Viljanen T, et al. Adenocarcinoma of the esophagus and the esophagogastric junction: positron emission tomography improves staging and prediction of survival in distant but not in locoregional disease. J Gastrointest Surg 2004; 8: 988–96
   PubMedGoogle Scholar
• Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OSH, Stoker J, Fockens P, , et al. Computed tomography, endosonography and FDG-positron emission tomography to assess neoadjuvant therapy response in esophageal cancer: a systematic review. Radiology 2005;236:841–51.
   PubMed Web of Science ®Google Scholar
• Griffith JF, Chan AC, Chow LT, Leung SF, Lam YH, Liang EY, et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 1999; 72: 678–84
   PubMedGoogle Scholar
• Jones DR, Parker LA, Jr, Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999; 85: 1026–32
   PubMed Web of Science ®Google Scholar
• Kroep JR, Van Groeningen CJ, Cuesta MA, Craanen ME, Hoekstra OS, Comans EF, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 2003; 5: 337–46
   PubMedGoogle Scholar
• Walker SJ, Allen SM, Steel A, Cullen MH, Matthews HR. Assessment of the response to chemotherapy in oesophageal cancer. Eur J Cardiothorac Surg 1991; 5: 519–22
   PubMedGoogle Scholar
• Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000; 66: 827–31
   PubMed Web of Science ®Google Scholar
• Bowrey DJ, Clark GW, Roberts SA, Hawthorne AB, Maughan TS, Williams GT, et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 1999; 3: 462–7
   PubMed Web of Science ®Google Scholar
• Chak A, Canto MI, Cooper GS, Isenberg G, Willis J, Levitan N, et al. Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients. Cancer 2000; 88: 1788–95
   PubMed Web of Science ®Google Scholar
• Dittler HJ, Bollschweiler E, Siewert JR. [What is the value of endosonography in the preoperative staging of esophageal carcinoma?]. Dtsch Med Wochenschr 1991; 116: 561–6
   PubMedGoogle Scholar
• Giovannini M, Seitz JF, Thomas P, Hannoun-Levy JM, Perrier H, Resbeut M, et al. Endoscopic ultrasonography for assessment of the response to combined radiation therapy and chemotherapy in patients with esophageal cancer. Endoscopy 1997; 29: 4–9
   PubMed Web of Science ®Google Scholar
• Hirata N, Kawamoto K, Ueyama T, Masuda K, Utsunomiya T, Kuwano H. Using endosonography to assess the effects of neoadjuvant therapy in patients with advanced esophageal cancer. Am J Roentgenol 1997; 169: 485–91
   PubMed Web of Science ®Google Scholar
• Hordijk ML, Kok TC, Wilson JH, Mulder AH. Assessment of response of esophageal carcinoma to induction chemotherapy. Endoscopy 1993; 25: 592–6
   PubMed Web of Science ®Google Scholar
• Isenberg G, Chak A, Canto MI, Levitan N, Clayman J, Pollack BJ, et al. Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation. Gastrointest Endosc 1998; 48: 158–63
   PubMed Web of Science ®Google Scholar
• Laterza E, de Manzoni G, Guglielmi A, Rodella L, Tedesco P, Cordiano C. Endoscopic ultrasonography in the staging of esophageal carcinoma after preoperative radiotherapy and chemotherapy. Ann Thorac Surg 1999; 67: 1466–9
   PubMed Web of Science ®Google Scholar
• Rice TW, Boyce GA, Sivak MV, Adelstein DJ, Kirby TJ. Esophageal carcinoma: esophageal ultrasound assessment of preoperative chemotherapy. Ann Thorac Surg 1992; 53: 972–7
   PubMed Web of Science ®Google Scholar
• Willis J, Cooper GS, Isenberg G, Sivak MV, Jr, Levitan N, Clayman J, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002; 55: 655–61
   PubMed Web of Science ®Google Scholar
• Zuccaro G, Jr, Rice TW, Goldblum J, Medendorp SV, Becker M, Pimentel R, et al. Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer. Am J Gastroenterol 1999; 94: 906–12
   PubMed Web of Science ®Google Scholar
• Arslan N, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy-2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging Biol 2002; 4: 301–10
   PubMedGoogle Scholar
• Brucher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001; 233: 300–9
   PubMed Web of Science ®Google Scholar
• Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003; 21: 428–32
   PubMed Web of Science ®Google Scholar
• Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13: 361–8
   PubMed Web of Science ®Google Scholar
• Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002; 184: 279–83
   PubMedGoogle Scholar
• Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058–65
   PubMed Web of Science ®Google Scholar
• Wieder HA, Brucher BL, Zimmermann F, Becker K, Lordick F, Beer A, et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004; 22: 900–8
   PubMed Web of Science ®Google Scholar
• Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680–6
   PubMed Web of Science ®Google Scholar
• Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, et al. Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78: 1152–60
   PubMed Web of Science ®Google Scholar
• Shreve P. Establishing a PET/CT practice. Am J Roentgenol 2005; 184 Suppl 5: S146–51
   Google Scholar